tradingkey.logo

C4 Therapeutics Inc <CCCC.OQ> expected to post a loss of 38 cents a share - Earnings Preview

ReutersJul 28, 2025 12:56 PM
  • C4 Therapeutics Inc CCCC.OQ CCCC.O is expected to show a fall in quarterly revenue when it reports results on July 30 (estimated) for the period ending June 30 2025

  • The Watertown Massachusetts-based company is expected to report a 45.4% decrease in revenue to $6.55 million from $12.01 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for C4 Therapeutics Inc is for a loss of 38 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for C4 Therapeutics Inc is $7.00, about 67.7% above its last closing price of $2.26

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Mar. 31 2025

-0.48

-0.45

-0.37

Beat

17.8

Dec. 31 2025

-0.47

-0.48

-0.49

Missed

-2.6

Sep. 30 2024

-0.36

-0.38

-0.35

Beat

7.9​

Jun. 30 2024

-0.37

-0.37

-0.26

Beat

30

​​Mar. 31 2024

-0.36

-0.35

-0.41

Missed

-16.7

Dec. 31 2023

-0.64

-0.68

-0.70

Missed

-2.6​

Sep. 30 2023

-0.67

-0.66

-0.52

Beat

21.2

Jun. 30 2023

-0.69

-0.69

-0.73

Missed

-6.1

This summary was machine generated July 28 at 12:56 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI